Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2014-02, Vol.28 (2), p.440-443
Hauptverfasser:	Récher, C, Béné, M C, Lioure, B, Pigneux, A, Vey, N, Delaunay, J, Luquet, I, Hunault, M, Guyotat, D, Bouscary, D, Fegueux, N, Jourdan, E, Lissandre, S, Escoffre-Barbe, M, Bonmati, C, Randriamalala, E, Guièze, R, Ojeda-Uribe, M, Dreyfus, F, Harousseau, J L, Cahn, J Y, Ifrah, N, Guardiola, P
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/67/1990/283/1897 692/700/565/1436 Acute myeloid leukemia Adolescent Adult Age Factors Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Chemotherapy Comparative analysis Critical Care Medicine Cytogenetics Daunorubicin Daunorubicin - administration & dosage Dosage and administration Drug therapy Follow-Up Studies Health aspects Hematology Hematopoietic Stem Cell Transplantation Humans Idarubicin Idarubicin - administration & dosage Immunology Induction therapy Innate immunity Intensive Internal Medicine letter-to-the-editor Letters to the editor Leukemia Leukemia, Myeloid, Acute Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Life Sciences Medical prognosis Medicine Medicine & Public Health Middle Aged Oncology Patient outcomes Remission (Medicine) Remission Induction Stem cell transplantation Transplantation, Homologous Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2013.290